ClinicalTrials.gg
RecruitingNCT06987383VENTURAUpdated Oct 28, 2026

Vibegron for ENergy Thinking and Resilience in Aging

A Phase 3 interventional study of Vibegron and Placebo in Obesity, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Wake Forest University Health Sciences · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Obesity by Wake Forest University Health Sciences — 3 open to participants now, 4 under way, 1 of them phase 3. Obesity · Wake Forest University Health Sciences.

Planned enrollment
25th of 39
40 · median 88
Started
2026
with 1 other
Phase 3
Only one
of the 45
Registered
44th of 45
by date

Among the 45 studies in Obesity by Wake Forest University Health Sciences, this one is the 25th largest by planned enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 3, and was the 44th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 45 studies in Obesity by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Obesity by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.

Read the detailed description

Aging is characterized by the gradual loss of physiological integrity, and this process may be accelerated in the presence of obesity, increasing susceptibility to disease, frailty, and death. Although the shared molecular pathways involved have not been fully elucidated, adipose tissue dysfunction is likely a key contributor to multisystem functional decline in aging and obesity. Despite growing evidence that β3 adrenergic receptor (β3AR) mediated activation of brown adipose tissue (BAT) may alter pathophysiological pathways implicated in various aging-related diseases including metabolic, cardiovascular, and neurodegenerative diseases, BAT has been largely ignored in aging research. This study will randomize 40 middle-aged and older adults (45-75 yrs) with obesity to the β3AR agonist Vibegron (75 mg/day) or placebo for 12 weeks to compare their effects on various bioenergetic, cardiometabolic, physical function, and cognitive outcomes. Potential study candidates will be screened by telephone to determine basic interest and eligibility. Individuals who pass this initial screening will then undergo an in-person screening at Atrium Health Wake Forest Baptist. Enrolled participants will be randomized 1:1 to Vibegron or placebo and will be instructed to take the study drug by mouth once daily for 12 weeks. Study outcomes will be assessed at the baseline and follow-up visits and at one safety/compliance visit. Participants will self-report demographic, behavioral, and medical information using questionnaires. They will also complete functional tests to assess muscle strength/power and mobility, DXA and CT scans to assess body composition and body fat distribution, and remote monitoring to assess core body temperature. In addition, participants will have their blood drawn for the assessment of glucose/insulin and lipid indices, for screening and safety purposes, and for storage of plasma/serum samples. Blood samples will also be used to assess mitochondrial bioenergetics in peripheral blood mononuclear cells and thermogenic and adipokine protein expression in adipose tissue-derived small extracellular vesicles. Safety will be assessed based on treatment-related adverse events and measurement of blood chemistries and vitals. To assess medication adherence, participants will be instructed to keep a daily dosing diary and to bring the log, along with empty pill bottles, to the safety/compliance visit for review by the study team.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Vibegron
  • aging
  • metabolism
  • physical function
  • cognitive function
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Obese ( ≥30 kg/m2 or BMI ≥27 kg/m2 with a waist circumference >102 cm for men and >88 cm for women)

Exclusion criteria

Exclusion Criteria:

  • Body weight ≥450 pounds
  • Major depression
  • Evidence of cognitive impairment
  • Uncontrolled diabetes ( >7%)
  • Weight gain or loss of ≥5% over the past 6 months
  • Prior weight loss procedure (e.g., gastric bypass, sleeve gastrectomy, gastric banding)
  • Regular use of the following: weight loss medications (e.g., Orlistat, Belviq, Contrave, Saxenda, Phentermine, Qsymia); medications or dietary supplements known to alter energy metabolism; adrenergic agonists or beta blockers
  • Symptoms of urinary retention, incontinence, urgency, and frequency or current use of an antimuscarinic medication to treat overactive bladder
  • Benign prostate hyperplasia
  • Significant medical illness or organ failure, such as uncontrolled hypertension, advanced kidney disease, liver disease, thyroid disease, or active neoplastic disease
  • Diagnosis of a neurodegenerative illness (e.g., mild cognitive impairment, dementia, Parkinson's disease, Multiple Sclerosis)
  • History of a stroke
  • Cardiac arrhythmia or an abnormal
  • Drug/substance abuse or excessive alcohol use within the past 6 months
  • to Vibegron or any of its components
  • Current participation in another intervention or research study that prohibits co-enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Vibegron

    Participants in this arm will take 75mg/day Vibegron for 12 weeks.

    Drug: Vibegron

  • Placebo comparator
    Placebo

    Participants in this arm will take placebo daily for 12 weeks.

    Drug: Placebo

Interventions

  • A drug in a class of medications called beta-3 adrenergic agonists; approved for use with Overactive Bladder; 75mg tablets will be used in this study

    Also known as: Gemtesa

  • DrugPlacebo

    Tablets made of inert substance that looks like the vibegron tablets but has no therapeutic value

06

What researchers measure

Primary outcomes

  1. Resting Metabolic Rate

    Resting metabolic rate (RMR) will be measured by indirect calorimetry using a computerized metabolic cart that provides valid and reliable measurement of oxygen consumption and carbon dioxide production - RMR can be estimated using formulas such as the Mifflin-St Jeor equation: Males: RMR = 10 \* weight (kg) + 6.25 \* height (cm) - 5 \* age (years) + 5 Females: RMR = 10 \* weight (kg) + 6.25 \* height (cm) - 5 \* age (years) - 161

    Time frame: Baseline

  2. Resting Metabolic Rate

    Resting metabolic rate (RMR) will be measured by indirect calorimetry using a computerized metabolic cart that provides valid and reliable measurement of oxygen consumption and carbon dioxide production - RMR can be estimated using formulas such as the Mifflin-St Jeor equation: Males: RMR = 10 \* weight (kg) + 6.25 \* height (cm) - 5 \* age (years) + 5 Females: RMR = 10 \* weight (kg) + 6.25 \* height (cm) - 5 \* age (years) - 161

    Time frame: Week 12

Secondary outcomes

  1. Glucose Tolerance Level

    Glucose tolerance will be assessed using a standard 75-g oral glucose load to measure changes in glucose and insulin levels. Glucose tolerance will be defined as the 2-hour glucose level - a normal two-hour post-glucose level is below 140 mg/dL (7.8 mmol/L). Levels between 140 and 199 mg/dL (7.8 and 11 mmol/L) indicate impaired glucose tolerance (also called prediabetes), while levels of 200 mg/dL (11.1 mmol/L) or higher suggest diabetes.

    Time frame: Baseline and Week 12

  2. Expanded Short Physical Performance Battery (eSPPB)

    Lower extremity function will be assessed using the eSPPB which measures balance, gait speed, and leg strength - Each component is scored separately, and then the scores are summed to give a total score ranging from 0 (worst) to 12 (best) - The total score is calculated by summing the scores from the three subtests. A higher total score indicates better lower extremity function, while a lower score indicates more functional limitations.

    Time frame: Baseline and Week 12

Other outcomes

  1. Core body temperature

    Core body temperature will be measured continuously using a temperature monitoring patch worn on the chest.

    Time frame: Baseline and Week 12

  2. Lipid levels

    Plasma levels of total cholesterol, VLDL cholesterol, HDL cholesterol, and triglycerides will be measured in fasted blood samples.

    Time frame: Baseline, Week 4, and Week 12

  3. Depressive Symptoms: 15-item Geriatric Depression Scale (GDS-15)

    Questionnaire used to measure depressive symptoms in the elderly; ranges from 0-15 with higher scores indicating greater severity of depression; score of 0-4 is within normal range; score of 5-8 mild depression; score of 9-11 moderate depression; score of 12-15 severe depression

    Time frame: Baseline and Week 12

  4. Quality of Life: Medical Outcomes Study Short Form 36 (SF-36)

    Quality of life questionnaire with a score that ranges from 0 to 100 with higher scores indicating better quality of life.

    Time frame: Baseline and Week 12

  5. Compliance Rate

    Compliance will be defined based on the number of daily doses taken relative to the total number of doses prescribed.

    Time frame: Baseline, Week 4, and Week 12

07

Study locations

1 of 1 sites recruiting
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
    Recruiting
    • Tina E Brinkley, PhD · Contact336-713-8534
    • Charlotte Crotts · Contact336-713-8503
    • Tina E Brinkley, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2028, 21 months after the start.

Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's planned 21 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 23, 2025
StartActual
Oct 27, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
Wake Forest University Health Sciences is now Recruiting
Oct 28, 2026
Start date
Oct 2026→Oct 27, 2026 (actual)
moved 2 times, Sep 29, 2026 – Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Wake Forest University Health Sciences · Winston-Salem, United StatesContact added •••8503
Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    Wake Forest University Health Sciences is now Recruiting
    Start date Nov 2026→Oct 27, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Wake Forest University Health Sciences · Winston-Salem, United StatesContact added •••8503
    + 1 other change: verification date
  2. Sep 29, 2026
    Start date Oct 2026→Nov 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06987383
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Oct 27, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Tina E. Brinkley, PhD
Contact
tbrinkle@wakehealth.edu
336-713-8534
Tina E Brinkley, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vibegron

Start the discussion